Seasonal Influenza Vaccine Market

Executive Summary

Seasonal Influenza Vaccine Market was valued at US $7.66 billion in 2021 and is projected to grow at 9.06% CAGR over the forecast period to reach US $12.88 billion by 2027. Seasonal Influenza Vaccine Market represented US $1.22 billion opportunity over 2019-2021 and estimated to create US $5.23 billion opportunity in 2027 over 2021.

Seasonal Influenza Vaccine from Consainsights analyses the Seasonal Influenza Vaccine Market in the Life Sciences industry over the forecast period to 2027.

Seasonal Influenza Vaccine research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Seasonal Influenza Vaccine segmentation includes Product Type, Age Group, Region and Geography.

Based on the Product Type, the Seasonal Influenza Vaccine analysis covers TYPE A (H1N1), TYPE A (H3N2), TYPE B.

In Product Type segment, TYPE A (H1N1) segment has highest cagr growth of 8.01%.

Based on the Age Group, the Seasonal Influenza Vaccine analysis covers PEDIATRICS, ADOLESCENCE, ADULTS, ELDERLY.

In Age Group segment, PEDIATRICS segment has highest cagr growth of 8.01%.

Based on the Region, the Seasonal Influenza Vaccine analysis covers EUROPE, ASIA-PACIFIC, LAMEA.

In Region segment, EUROPE segment has highest cagr growth of 8.01%.

Based on the region, the Seasonal Influenza Vaccine analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include GLAXOSMITHKLINE PLC, SINOVAC BIOTECH LTD., CHANGSHENG BIO-TECHNOLOGY CO., LTD., CCBIO SA, ALEPH BIOMEDICAL, SANOFI S.A., JIANGSU SIMCERE VAXTEC BIO-PHARMACEUTICAL CO., LTD., DALIAN HISSEN BIO-PHARM, ABBOTT LABORATORIES, NOVARTIS INTERNATIONAL AG and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Product Type

Introduction

In 2021, TYPE A (H1N1) segment has the highest revenue of US $3.29 billion and is expected to grow at CAGR of 8.01% by 2027 TYPE A (H1N1) segment has highest cagr growth of 8.01%.

TYPE A (H1N1)

TYPE A (H1N1) segment was valued at US $2.76 billion in 2019 and is projected to grow at 8.01% CAGR over the forecast period to reach US $5.53 billion by 2027. TYPE A (H1N1) segment represented US $0.52 billion opportunity over 2019-2021 and estimated to create US $2.24 billion opportunity in 2027 over 2021.

TYPE A (H3N2)

TYPE A (H3N2) segment was valued at US $1.58 billion in 2019 and is projected to grow at 8.01% CAGR over the forecast period to reach US $3.16 billion by 2027. TYPE A (H3N2) segment represented US $0.30 billion opportunity over 2019-2021 and estimated to create US $1.28 billion opportunity in 2027 over 2021.

TYPE B

TYPE B segment was valued at US $2.09 billion in 2019 and is projected to grow at 8.01% CAGR over the forecast period to reach US $4.19 billion by 2027. TYPE B segment represented US $0.40 billion opportunity over 2019-2021 and estimated to create US $1.70 billion opportunity in 2027 over 2021.

Age Group

Introduction

In 2021, PEDIATRICS segment has the highest revenue of US $4.28 billion and is expected to grow at CAGR of 8.01% by 2027 PEDIATRICS segment has highest cagr growth of 8.01%.

PEDIATRICS

PEDIATRICS segment was valued at US $3.60 billion in 2019 and is projected to grow at 8.01% CAGR over the forecast period to reach US $7.20 billion by 2027. PEDIATRICS segment represented US $0.68 billion opportunity over 2019-2021 and estimated to create US $2.92 billion opportunity in 2027 over 2021.

ADOLESCENCE

ADOLESCENCE segment was valued at US $1.91 billion in 2019 and is projected to grow at 8.01% CAGR over the forecast period to reach US $3.82 billion by 2027. ADOLESCENCE segment represented US $0.36 billion opportunity over 2019-2021 and estimated to create US $1.55 billion opportunity in 2027 over 2021.

ADULTS

ADULTS segment was valued at US $0.91 billion in 2019 and is projected to grow at 8.01% CAGR over the forecast period to reach US $1.83 billion by 2027. ADULTS segment represented US $0.17 billion opportunity over 2019-2021 and estimated to create US $0.74 billion opportunity in 2027 over 2021.

ELDERLY

ELDERLY segment was valued at US $0.02 billion in 2019 and is projected to grow at 8.01% CAGR over the forecast period to reach US $0.03 billion by 2027. ELDERLY segment represented US $0.00 billion opportunity over 2019-2021 and estimated to create US $0.01 billion opportunity in 2027 over 2021.

Region

Introduction

In 2021, EUROPE segment has the highest revenue of US $3.66 billion and is expected to grow at CAGR of 8.01% by 2027 EUROPE segment has highest cagr growth of 8.01%.

EUROPE

EUROPE segment was valued at US $3.08 billion in 2019 and is projected to grow at 8.01% CAGR over the forecast period to reach US $6.15 billion by 2027. EUROPE segment represented US $0.58 billion opportunity over 2019-2021 and estimated to create US $2.50 billion opportunity in 2027 over 2021.

ASIA-PACIFIC

ASIA-PACIFIC segment was valued at US $2.33 billion in 2019 and is projected to grow at 8.01% CAGR over the forecast period to reach US $4.65 billion by 2027. ASIA-PACIFIC segment represented US $0.44 billion opportunity over 2019-2021 and estimated to create US $1.89 billion opportunity in 2027 over 2021.

LAMEA

LAMEA segment was valued at US $1.04 billion in 2019 and is projected to grow at 8.01% CAGR over the forecast period to reach US $2.07 billion by 2027. LAMEA segment represented US $0.20 billion opportunity over 2019-2021 and estimated to create US $0.84 billion opportunity in 2027 over 2021.